{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fras-inhibitors-for-pdac-lY5Ir7hc","width":444,"version":"1.0","type":"rich","title":"Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/e4f4e120-9b34-4910-b0ce-8bebb9defc1d/101525_pdac_ras3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/7e0d7a30-744c-4dfc-9f06-d304bedc569f\" height=\"200\" width=\"100%\" title=\"Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, as they discuss novel RAS-targeted therapies for pancreatic cancer, including optimal KRAS mutation testing, emerging multiselective RAS inhibitors, and combination strategies."}